{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:15:04Z","timestamp":1791807304811,"version":"4.3.4"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Singhealth Medicine Academic Clinical Programme","award":["NCRS 03FY2021\/P2\/10-A91"],"award-info":[{"award-number":["NCRS 03FY2021\/P2\/10-A91"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Systemic corticosteroids for 5\u20137\u2009days are standard care for asthma exacerbations, but the optimal duration and potential for precision prescribing remain unclear. Biomarker-guided approaches could reduce corticosteroid exposure without compromising outcomes. We aimed to evaluate whether the blood eosinophil count can be used to safely reduce systemic corticosteroid exposure in hospitalised asthma exacerbations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, two-centre randomised trial, adults hospitalised for asthma exacerbation were assigned 1:1 to usual care (5 days prednisolone) or eosinophil-guided care using blood eosinophil counts obtained prior to corticosteroid administration (3 days if eosinophils &lt;300\u2009cells\/\u00b5L; 5 days if \u2265300\u2009cells\/\u00b5L). The primary outcome was non-inferiority of treatment failure rates (composite of extension of steroid duration, mechanical ventilation or death), with a prespecified 20% non-inferiority margin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 110 randomised patients (55 per group), 60% were eosinophilic, and 40% non-eosinophilic. Treatment failure occurred in 6\/55 (10.9%) of eosinophil-guided versus 4\/55 (7.3%) of usual care patients, with a 3.6% absolute difference (95% CI \u22128.9% to 16.2%), meeting non-inferiority. Cumulative corticosteroid dose per patient was similar between groups but significantly lower for non-eosinophilic than eosinophilic exacerbations in the eosinophil-guided group (136 vs 214\u2009mg; p=0.0004), a difference not observed in usual care (186 vs 211\u2009mg; p=0.18). Length of stay, Asthma Control Questionnaire-5 change, additional steroid bursts at 14 days or time to next exacerbation up to 1 year showed no significant differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eosinophil-guided therapy safely reduced systemic corticosteroid exposure in non-eosinophilic exacerbations while maintaining non-inferior outcomes in this proof-of-concept trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05417906\">NCT05417906<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223961","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:25:40Z","timestamp":1764786340000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial"],"prefix":"10.1136","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct05417906","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05417906","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0884-2507","authenticated-orcid":false,"given":"Anthony","family":"Yii","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunn Ren","family":"Tay","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken Cheah Hooi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Yuan","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Yu-Fang","family":"Sieow","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue Ning","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Ren","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean Chee Hong","family":"Loh","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Yee","family":"Tiew","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore"},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jansen Meng Kwang","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine K H","family":"Tee","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-0129","authenticated-orcid":false,"given":"Mariko Siyue","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore"},{"name":"Duke-National University of Singapore Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026021621450640000_81.3.238.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"2026021621450640000_81.3.238.2","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. 2024."},{"key":"2026021621450640000_81.3.238.3","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/cea.13465","article-title":"Blood eosinophil count correlates with severity of respiratory failure in life\u2010threatening asthma and predicts risk of subsequent exacerbations","volume":"49","author":"Yii","year":"2019","journal-title":"Clin Experimental Allergy"},{"key":"2026021621450640000_81.3.238.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.02.013"},{"key":"2026021621450640000_81.3.238.5","article-title":"Different oral corticosteroid regimens for acute asthma","volume":"2016","author":"Normansell","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021621450640000_81.3.238.6","unstructured":"UpToDate . Acute exacerbations of asthma in adults: emergency department and inpatient management. 2024. Available: https:\/\/www.uptodate.com\/contents\/acute-exacerbations-of-asthma-in-adults-emergency-department-and-inpatient-management?search=asthma%20exacerbation%20adult&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1614788092"},{"key":"2026021621450640000_81.3.238.7","unstructured":"Scottish Intercollegiate Guidelines Network and British Thoracic Society . British guideline on the management of asthma. 2019."},{"key":"2026021621450640000_81.3.238.8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370120137023"},{"key":"2026021621450640000_81.3.238.9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2169\/internalmedicine.39.794","article-title":"Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study","volume":"39","author":"Hasegawa","year":"2000","journal-title":"Intern Med"},{"key":"2026021621450640000_81.3.238.10","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2002.1369"},{"key":"2026021621450640000_81.3.238.11","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90134-3"},{"key":"2026021621450640000_81.3.238.12","first-page":"543","article-title":"A comparison of a 3 day course with a 2 week course of oral prednisolone in patients with chronic asthma","volume":"47","author":"Hasegawa","year":"1998","journal-title":"Arerugi"},{"key":"2026021621450640000_81.3.238.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.013"},{"key":"2026021621450640000_81.3.238.14","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.3.232"},{"key":"2026021621450640000_81.3.238.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.07.014"},{"key":"2026021621450640000_81.3.238.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.02.042"},{"key":"2026021621450640000_81.3.238.17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02391-2024","article-title":"Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)","volume":"65","author":"Celis-Preciado","year":"2025","journal-title":"Eur Respir J"},{"key":"2026021621450640000_81.3.238.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205634"},{"key":"2026021621450640000_81.3.238.19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.13496","article-title":"Precision medicine in united airways disease: A \u201ctreatable traits\u201d approach","volume":"73","author":"Yii","year":"2018","journal-title":"Allergy"},{"key":"2026021621450640000_81.3.238.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"2026021621450640000_81.3.238.21","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219642"},{"key":"2026021621450640000_81.3.238.22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/resp.70077","article-title":"The Risk-Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand","volume":"30","author":"Howell","year":"2025","journal-title":"Respirology"},{"key":"2026021621450640000_81.3.238.23","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91076-8"},{"key":"2026021621450640000_81.3.238.24","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.073429"},{"key":"2026021621450640000_81.3.238.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01813-9"},{"key":"2026021621450640000_81.3.238.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.3.565"},{"key":"2026021621450640000_81.3.238.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00137704"},{"key":"2026021621450640000_81.3.238.28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/cea.13106","article-title":"Step-down of inhaled corticosteroids in non-eosinophilic asthma: A prospective trial in real life","volume":"48","author":"Demarche","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2026021621450640000_81.3.238.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0129OC"},{"key":"2026021621450640000_81.3.238.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0347-8"},{"key":"2026021621450640000_81.3.238.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201108-1553OC"},{"key":"2026021621450640000_81.3.238.32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S2213-2600(23)00298-9","article-title":"Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial","volume":"12","author":"Ramakrishnan","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026021621450640000_81.3.238.33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","article-title":"Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial","volume":"7","author":"Sivapalan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026021621450640000_81.3.238.34","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0432"},{"key":"2026021621450640000_81.3.238.35","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S176026"},{"key":"2026021621450640000_81.3.238.36","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.jaip.2020.06.055","article-title":"Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma","volume":"8","author":"Zeiger","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026021621450640000_81.3.238.37","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14147"},{"key":"2026021621450640000_81.3.238.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"2026021621450640000_81.3.238.39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40521-023-00330-z","article-title":"Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option","volume":"10","author":"McDowell","year":"2023","journal-title":"Curr Treat Options Allergy"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:45:24Z","timestamp":1771307124000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/thorax-2025-223961"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223961","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}